FDA Guidance to Confirm Hypogonadism with Two Morning Tests

Key takeaways

• Confirm low T with symptoms plus two separate early-morning, fasting total testosterone values below your lab’s reference range.
• Avoid afternoon or non-fasting blood draws; diurnal variation can lower results later in the day.
• Check LH/FSH and prolactin to distinguish primary from secondary hypogonadism and rule out reversible causes.
• FDA (2025) removed the boxed cardiovascular warning, added a class-wide blood pressure warning, and kept the limitation of use (not for age-related low T without a medical cause).
• Borderline or mismatched results warrant repeat testing and cause-finding before starting TRT.

Overview

Many men want a clear, credible path to diagnose low testosterone. FDA guidance sets a straightforward standard: confirm hypogonadism with two separate early-morning, fasting total testosterone results below your lab’s normal range, plus consistent symptoms—and rule out secondary causes—before starting therapy. Use this guide to prepare for an informed conversation with your clinician.

What the FDA requires to confirm hypogonadism

• Consistent symptoms or signs of androgen deficiency (for example, reduced libido or erectile dysfunction).
• Two separate early-morning, fasting total testosterone measurements below your laboratory’s reference range. Many references use approximately <12 nmol/L (about <300–350 ng/dL), but lab cut-offs vary.
• Accurate testing methodology using high-quality, standardized assays (ideally participating in CDC standardization programs).
• Confirmation of a medical cause. Testosterone products are not indicated for age-related low T without an identified cause (limitation of use remains).

A single low value—especially from an afternoon, non-fasting draw—is not enough. Both the numbers and the clinical picture must align.

Why morning, fasting tests matter

Testosterone peaks in the morning and declines through the day; afternoon levels can be 30–50% lower. Food intake can modestly reduce measured levels as well.

• Get tested early morning (commonly 8–10 AM).
• Fast before the draw unless your clinician instructs otherwise.
• Repeat the test on a different morning to confirm the finding.

These steps reduce variability and help your clinician interpret results with confidence.

Interpreting the numbers: thresholds and units

• Total testosterone thresholds: Many guidelines align around a biochemical definition below roughly 12 nmol/L (about <300–350 ng/dL), confirmed twice, when paired with symptoms.
• Borderline values: Results in the “equivocal” range (roughly 8–12 nmol/L) often merit careful reassessment, repeat measurements, and evaluation for underlying causes.
• Lab-specific ranges: Always interpret results against the reference interval reported by your testing lab.

Your clinician may also account for conditions that alter sex hormone–binding globulin (SHBG), which can influence total testosterone. In selected borderline cases, a calculated free testosterone (from SHBG and albumin) may be added. The core FDA requirement remains two low morning total testosterone results plus consistent symptoms.

Symptoms should match the labs

Numbers alone do not make the diagnosis. The most consistently responsive symptoms in randomized trials include:

• Decreased libido
• Erectile dysfunction

Other features may be present but can be less specific. A careful symptom history helps ensure any potential therapy targets the right problem.

Rule out secondary causes before considering TRT

After confirming low testosterone twice, the next step is cause-finding. Treating an underlying issue may normalize testosterone—or clarify whether TRT is appropriate and safe.

Key labs and interpretations:

• LH and FSH: High LH/FSH with low T suggests primary testicular failure; low or inappropriately normal LH/FSH with low T suggests secondary (pituitary/hypothalamic) hypogonadism.
• Prolactin: Elevated levels can suppress gonadotropins and lower testosterone; marked elevations may warrant pituitary evaluation.
• Thyroid function (e.g., TSH): Thyroid disorders can contribute to symptoms and confound interpretation.

Clinical context to review:

• Obesity and metabolic health: Excess adiposity can suppress testosterone; clinicians often address weight and metabolic risk factors as part of care.
• Medications and substances: Opioids and certain other agents can suppress the hypothalamic–pituitary–gonadal axis.
• Pituitary/hypothalamic disease: Headaches, visual changes, or a history suggestive of pituitary dysfunction merit targeted evaluation.

Addressing reversible drivers may improve testosterone without TRT—or better define when TRT is appropriate.

Recent FDA label changes: what they mean

• Cardiovascular risk: On February 28, 2025, the FDA removed the boxed warning regarding major adverse cardiovascular events after data from the 2023 TRAVERSE trial showed no significant difference versus placebo (hazard ratio ~0.96).
• Blood pressure: Class-wide labeling now includes strengthened warnings for increased blood pressure based on ambulatory BP monitoring studies.
• Limitation of use remains: Testosterone is not approved for age-related low T without an identified medical cause.

Implications for patients:

• Assess and monitor blood pressure regularly when starting or continuing TRT.
• The removal of the boxed warning does not mean risk-free therapy; individualized risk assessment and monitoring remain essential.
• The diagnostic standard is unchanged: two low morning T levels plus symptoms, with secondary causes considered, before TRT.

Borderline or mismatched results: next steps

• Repeat early-morning, fasting total testosterone on a separate day.
• Ensure high-quality, standardized assays were used.
• Evaluate for secondary causes (LH/FSH, prolactin, thyroid function) and reversible contributors (e.g., obesity, certain medications).
• Reassess the full clinical picture rather than reflexively starting—or dismissing—TRT.

There is active research into “functional hypogonadism,” especially in obesity, and how weight-loss strategies—including emerging metabolic therapies—may compare with or complement TRT. If you are in this borderline group, a tailored plan with your clinician is key.

Common testing mistakes to avoid

• Relying on a single measurement
• Afternoon or non-fasting blood draws
• Interpreting values without the lab’s reference range
• Skipping LH/FSH (and prolactin/TSH when indicated)
• Moving to treatment before cause-finding

A practical checklist for your appointment

• Request two early-morning (8–10 AM), fasting total testosterone tests on different days, ideally with a CDC-standardized lab.
• Ask to include LH and FSH with the second test; discuss prolactin and thyroid testing if appropriate.
• Prepare a brief symptom timeline (e.g., changes in libido or erections).
• List current medications and substances (e.g., opioids).
• Note relevant health factors (weight changes, sleep quality, prior pituitary or testicular issues).
• Ask how results will be interpreted against the lab’s reference range and what would prompt further evaluation.

At Taurus Meds, we support guideline-concordant TRT lab testing and follow-up, coordinating with licensed clinicians who can help interpret results, identify potential secondary causes, and discuss options suited to your health goals.

Conclusion

A trustworthy way to diagnose low testosterone exists, and it is intentionally conservative: two separate morning fasting total testosterone tests below the lab’s normal range, plus consistent symptoms, and a thoughtful search for secondary causes. This approach reduces misdiagnosis, clarifies when TRT is appropriate, and helps tailor care to the individual. Recent FDA label updates reinforce the importance of monitoring—particularly blood pressure—while maintaining the restriction against using TRT for age-related low testosterone without a medical cause. If you are considering TRT, start by getting the testing right and engage in shared decision-making with your clinician.

Disclaimer

This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare professional with any questions about a medical condition or treatment.

Sources

• FDA: Testosterone information (safety and labeling)
• FDA: Class-wide labeling changes for testosterone products
• PubMed reference on testosterone assessment
• FDA guidance document (PDF)
• This Changed My Practice: Testosterone testing for male hypogonadism